4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Basic information
- Product Name:
- 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
- Synonyms:
-
- 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
- (E)-4-(4-(4-(2-cyanovinyl)-2,6-diMethylphenylaMino)pyriMidin-2-ylaMino)benzonitrile
- 4-[[4-[[4-[(E)-2-Cyanovinyl]-2,6-diMethylphenyl]aMino]pyriMidin-2-yl]aMino]benzonitrile
- 4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-diMethylphenyl}aMino)pyriMidin-2-yl]aMino}benzonitrile
- Rilpivirine(R 278474
- Rilpivirine (R 278474, TMC 278)
- Rilpivirine
- 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
- CAS:
- 500287-72-9
- MF:
- C22H18N6
- MW:
- 366.42
- Product Categories:
-
- Aromatics
- Heterocycles
- Inhibitors
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Mol File:
- 500287-72-9.mol
4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Chemical Properties
- Melting point:
- 245℃
- Boiling point:
- 634.1±65.0 °C(Predicted)
- Density
- 1.27
- storage temp.
- Refrigerator
- solubility
- Acetone (Slightly), Chloroform (Slightly), DMSO (Slightly), Water (Very Slightly)
- pka
- 4.56±0.10(Predicted)
- form
- Solid
- color
- Yellow
Safety Information
- Hazardous Substances Data
- 500287-72-9(Hazardous Substances Data)
4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Usage And Synthesis
Description
In May 2011, the U.S. FDA approved rilpivirine in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) 1 infection in treatment-naive adult patients. Rilpivirine is a member of the nonnucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV agents. It is highly potent against a range of wild-type HIV strains (EC50=0.07–1.0 nM),～10–20 timesmore potent than the NNRTI efavirenz (Sustiva), and active against HIV strains resistant to other NNRTIs. The discovery of rilpivirine was guided by molecular modeling and X-ray crystallography of HIV-1 RT complexed with inhibitors. The synthesis of rilpivirine is accomplished by an efficient 6-step route in which the key step is coupling of 4-((4-chloropyrimidin-2-yl)amino)benzonitrile with (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile.
Chemical Properties
N/ABright Yellow Solid
Originator
Janssen (Belgium)
Uses
A novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. An anti-HIV agent.
Definition
ChEBI: An aminopyrimidine that is pyrimidine-2,4-diamine in which the amino groups at positions 2 and 4 are substituted by 4-cyanophenyl and 4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl groups respectively. Used for treatment of HIV.
brand name
Edurant
Clinical Use
Non-nucleoside reverse transcriptase inhibitor:
Treatment of progressive or advanced HIV infection
in combination with at least two other antivirals
target
reverse transcriptase
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: avoid with clarithromycin and
erythromycin - concentration possibly increased;
concentration decreased by rifampicin and rifabutin
- avoid with rifampicin, increase dose of rilpivirine
to 50 mg daily.
Antidepressants: concentration possibly reduced by
St John’s wort - avoid.
Antiepileptics: concentration possibly reduced
by carbamazepine, fosphenytoin, oxcarbazepine,
phenobarbital, primidone and phenytoin - avoid.
Corticosteroids: avoid with dexamethasone (except
as a single dose).
Orlistat: absorption possibly reduced by orlistat.
Ulcer-healing drugs: concentration possibly reduced
by esomeprazole, lansoprazole, omeprazole,
pantoprazole and rabeprazole - avoid; avoid
histamine H2
-antagonists for 12 hours before and 4
hours after rilpiverine.
Metabolism
Primarily undergoes oxidative metabolism mediated by
the cytochrome P450 (CYP) 3A system.
85% excreted via the faeces (25% as unchanged drug) and
6% via the urine.
storage
Store at -20°C
References
[1] moss d m, liptrott n j, curley p, et al. rilpivirine inhibits drug transporters abcb1, slc22a1, and slc22a2 in vitro. antimicrobial agents and chemotherapy, 2013, 57(11): 5612-5618.
[2] garvey l, winston a. rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. 2009.
[3] weiss j, haefeli w e. potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. international journal of antimicrobial agents, 2013, 41(5): 484-487.
[4] baert l, van’t klooster g, dries w, et al. development of a long-acting injectable formulation with nanoparticles of rilpivirine (tmc278) for hiv treatment. european journal of pharmaceutics and biopharmaceutics, 2009, 72(3): 502-508.
4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrileSupplier
- Tel
- 023-63134718 13048300200
- 1501533472@qq.com
- Tel
- +8618575662672 18575662672
- mzeng@3wpharm.com
- Tel
- 0576-89085261 15867635987
- jasonhu09@163.com
- Tel
- 027-027-83984790 17720532645
- t17720532645@163.com
- Tel
- sales@boylechem.com